Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 2Phase 4 1

Status

Unknown 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 37Breast 14Gynecologic 12Head & Neck 8Thoracic 6CNS 6Sarcoma 5Genitourinary 4Plasma cell 2Dermatologic 2Lymphoid 1

Conditions

Multiple Myeloma 2Neoplasms, Plasma Cell 1

Interventions

Dexamethasone 178Bortezomib 100Lenalidomide 90daratumumab 47Melphalan 46Thalidomide 44pomalidomide 43Cyclophosphamide 38Calcium Dobesilate 30carfilzomib 29Prednisone 19Doxorubicin 16elotuzumab 14Filgrastim 14isatuximab 12ixazomib 11Granulocyte Colony-Stimulating Factor 11Vincristine 10Peripheral Blood Stem Cell Transplantation 10dexamethasone acetate 9belantamab mafodotin 9Zoledronic Acid 8selinexor 7Epoetin Alfa 7fludarabine 6Etoposide 6dexamethasone 21-phosphate 5auricularum 5Mycophenolic Acid 5Cisplatin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Neoadjuvant Therapy × Plasma cell × Clear all
NCT01554852 2018-06-11

Myeloma XI

University of Leeds

Phase 3 Unknown
4,420 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

NCT00574080 2017-11-20

UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide

University of Arkansas

Phase 3 Terminated
20 enrolled 7 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡